Zydus and CSIR-CDRI Lucknow to develop drug for CKD induced Osteoporosis

Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism

DCGI approves Enzene biosimilar Denosumab for Osteoporosis

This is Enzene Biosciences third biosimilar to be approved

Biocon receives Health Canada approval for Bosaya and Vevzuo biosimilars to Prolia and Xgeva

Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market

Teva hits major biosimilar milestones with FDA nod and regulatory filings

The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia

Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan

Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema

BPL Medical Tech acquires South Korea’s Yozma BMtech

Launches advanced bone density systems in India & Dubai

Dr Reddy’s enters hormone replacement therapy market with landmark brand acquisition

The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India

Amneal and mAbxience score FDA green light for two Denosumab biosimilars

Teva breaks ground with EU approval for two key bone disease biosimilars